Standardizing on Masimo SET Allows Clinicians to Overcome the Limitations
of Conventional Pulse Oximetry, Offering Significant Clinical Advancements
IRVINE, Calif., June 3 /PRNewswire-FirstCall/ -- Masimo, the inventor of
Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion Pulse
Oximetry, today announced it has completed the conversion of Duke University
Hospital to Masimo SET pulse oximetry technology.
"Ultimately, the decision to convert to Masimo SET came down to what was
best for patients," said Tony Caruso, Senior Director of Clinical Engineering,
Duke University Health System in Durham, North Carolina. "It is critically
important for us to access technologies that result in improvements in patient
care. In this case, we believe we have improved our ability to increase
detection of true clinical events earlier."
"In the emergency department, there are many times when we don't have time
to second-guess our pulse oximeter performance, wonder whether the
measurements we are getting are accurate, or take excessive time to obtain a
reading," said Frank DeMarco, RN, emergency department clinical operations
director, Duke University Hospital. "This technology offers us improvements
over the system we had used previously and, hopefully, will contribute to more
effective clinical operations."
Masimo Founder and CEO, Joe E. Kiani, stated, "We are happy to be the
pulse oximetry standard-of-care solution chosen by the Duke University
Hospital system to noninvasively and continuously monitor their patients.
With the unprecedented accuracy and performance of Masimo SET, clinicians at
Duke are afforded the opportunity to better monitor, manage and treat patients
using advanced pulse oximetry capabilities that allow them to detect
life-threatening events earlier."
About Masimo
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care--helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low-Perfusion pulse
oximetry, known as Masimo SET(R), which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-OximetryTM, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHbTM), oxygen content (SpOCTM), carboxyhemoglobin (SpCO(R)), methemoglobin
(SpMet(R)), and PVITM, in addition to oxyhemoglobin (SpO2), pulse rate (PR),
and perfusion index (PI), allowing early detection and treatment of
potentially life-threatening conditions. Founded in 1989, Masimo has the
mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking
Noninvasive Monitoring to New Sites and Applications." Additional information
about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks related to our
assumption that Masimo SET and Masimo Rainbow SET will deliver a sufficient
level of clinical improvement over alternative pulse oximetry and noninvasive
patient monitoring solutions to allow for further adoption of the technology
at other hospitals, risks related to our assumption that Duke University
Hospital's system-wide conversion to Masimo technology will serve to
substantially increase revenues, as well as other factors discussed in the
"Risk Factors" section of our Quarterly Report on Form 10-Q for the fiscal
quarter year ended April 4, 2009, filed with the Securities and Exchange
Commission ("SEC") on May 6, 2009, which may be obtained for free at the SEC's
website at www.sec.gov. Although we believe that the expectations reflected in
our forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included in
this press release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of today's date. We do not
undertake any obligation to update, amend or clarify these forward-looking
statements or the "Risk Factors" contained in our Quarterly Report on Form
10-Q for the fiscal quarter year ended April 4, 2009, filed with the
Securities and Exchange Commission ("SEC") on May 6, 2009, whether as a result
of new information, future events or otherwise, except as may be required
under the applicable securities laws.
Contact:
Dana BanksMasimo Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8,
Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered
trademarks of Masimo Corporation. Other trademarks used herein are the
property of their respective owners.
SOURCE Masimo
-0- 06/03/2009
/CONTACT: Dana Banks of Masimo Corporation, +1-949-297-7348/
/Web Site: http://www.masimo.com /
(MASI)
CO: Masimo; Duke University Hospital
ST: California
IN: HEA MEQ CPR EDU HED
SU: PDT
PR
-- LA27300 --
0450 06/03/200915:35 EDThttp://www.prnewswire.com